What is fecal microbiota transplantation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

What is a Faecal Transplant?

Fecal microbiota transplantation (FMT) is a medical procedure that involves transferring processed stool from a rigorously screened healthy donor into the gastrointestinal tract of a recipient to restore a balanced gut microbiome and treat diseases related to gut microbial disruption. 1

Core Mechanism and Purpose

FMT works by administering fecal material containing distal gut microbiota from a healthy donor to a patient with dysbiosis (an alteration in their normal gut bacteria). The fundamental goal is to restore phylogenetic diversity and establish a microbiota composition more typical of a healthy individual 1. The gut microbiota functions with complexity comparable to an organ system, playing pivotal roles in metabolism, immune function, and maintaining gut homeostasis 1.

Historical Context

While FMT may sound novel, it has ancient roots:

  • Dating back to 4th century China, where human fecal suspensions were used orally to cure food poisoning and severe diarrhea 1
  • Used in veterinary medicine since the 17th century for treating ruminal disorders 1
  • First modern case series published in 1958 by American surgeon Ben Eiseman for pseudomembranous enterocolitis 1
  • First documented case of confirmed C. difficile infection treated with FMT reported in 1983 1

Current Clinical Applications

Established Use: Recurrent C. difficile Infection

The primary and most evidence-supported indication for FMT is recurrent Clostridioides difficile infection (CDI), where it achieves cure rates of 87-90% on average, with some reports as high as 100%. 1

According to the 2024 AGA guidelines 2:

  • In immunocompetent adults with recurrent CDI: FMT is suggested upon completion of standard antibiotic therapy to prevent recurrence
  • In mildly or moderately immunocompromised adults with recurrent CDI: Conventional FMT is suggested selectively
  • In severely immunocompromised adults: FMT is suggested against due to safety concerns
  • In hospitalized adults with severe or fulminant CDI not responding to standard antibiotics: FMT is suggested as an adjuvant treatment

Investigational Applications

While FMT shows promise for other conditions associated with gut dysbiosis, the 2024 AGA guidelines explicitly recommend against using FMT for inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) outside of clinical trials 2. Research continues exploring potential applications in:

  • Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
  • Irritable bowel syndrome
  • Metabolic syndrome and obesity
  • Autoimmune conditions
  • Neurological disorders

The Procedure

FMT involves several critical steps 3, 4, 5:

Donor Selection

Rigorous screening is essential, including:

  • Detailed questionnaires and interviews
  • Comprehensive blood tests
  • Stool examinations to exclude infectious agents

Delivery Methods

Multiple routes exist:

  • Colonoscopic infusion (traditional, widely accepted)
  • Oral capsules (gaining popularity due to safety and patient acceptability)
  • Upper gastrointestinal delivery
  • Enema administration

Stool Processing

  • Can be fresh, frozen, or freeze-dried
  • May involve anaerobic processing
  • Single donor or pooled donor material

Safety and Regulatory Considerations

Safety remains paramount, with particular attention to preventing infectious disease transmission and unwanted immune responses. 3 The regulatory landscape varies internationally:

  • The FDA classifies FMT as an investigational new drug (IND), typically requiring physicians to submit an IND application 4
  • Some nations categorize it as a biologic therapy or experimental treatment 3
  • Regulatory standards continue to evolve as the field matures

Important Caveats

  • Long-term safety data remains incomplete, necessitating careful follow-up of recipients 1
  • Donor-recipient variability significantly affects outcomes
  • Standardization of protocols is still evolving
  • The procedure is relatively simple to perform but requires strict adherence to safety protocols
  • The restoration of microbial communities persists durably after FMT, resembling those of the donor 1

Future Directions

The field is evolving toward more refined approaches 1:

  • Encapsulated formulations
  • Defined microbial consortia
  • Live biotherapeutic products (LBPs)
  • Moving beyond "whole stool" transplants to increase safety and tolerability

References

Related Questions

In an adult with recurrent Clostridioides difficile infection (CDI), what are the indications for fecal microbiota transplant (FMT) and the recommended procedure for its administration?
What are the criteria for a healthy donor for a fecal microbiota transplant (FMT)?
Can fecal microbiota transplantation (stool donation) be used to treat enteric colitis?
What is the target minute ventilation for an adult patient on mechanical ventilation?
In an adult with new, persistent dizziness, should a non‑contrast brain MRI be performed first, and when is gadolinium‑enhanced MRI indicated?
What pharmacologic treatment is recommended for dissociative disorder?
What are the characteristics of knee osteoarthritis pain?
Are stimulant medications indicated for treating dissociative disorders, and only if the patient has comorbid ADHD?
What are topical analgesics and how are they applied for the treatment of an anal fissure?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.